Vaxxinova US, originally called Epitopix, began as the laboratory service division of Willmar Poultry Company (WPC) in Willmar, Minnesota. During the 1980s, WPC began to seek innovative ways to improve the health of its turkey breeding stock. In order to combat Salmonella, E. coli, Pasteurella (fowl cholera), and Hemorrhagic Enteritis virus, WPC created a USDA licensed vaccine laboratory, and selected a premier team of scientists to pioneer novel vaccine technology. This team pursued a single vaccine that would prevent as many as 30 different serotypes of Salmonella commonly found in the production of poultry and livestock.
Through many years of research, the team developed ground-breaking technology in the form of Siderophore Receptor Protein (SRP) vaccines. This revolutionary vaccine immunizes against bacterial infections utilizing a cell-free purified extract of SRPs. By 1997, vaccine made from the combined SRP of Salmonella, E. coli, and P. multocida was in widespread use across the WPC breeder operations in Minnesota.
Epitopix, LLC was formed in 2002 to commercialize SRP technology, and to discover new vaccine technologies that improve animal health and human food safety. Discovery and development continues today, to bring novel vaccine products to additional markets including livestock, poultry, and companion animals. Epitopix owns intellectual property rights to all of its discoveries and has out-licensed SRP Technology development rights for human medical applications to Syntiron, LLC. In 2018, Epitopix became part of the Vaxxinova team to develop and distribute products in the United States, and in 2020 changed its name to Vaxxinova US to create a global branding strategy and unify its partnerships with its global affiliates. We continue to be privately held, and hold a USDA Establishment License No. 365 for the manufacturing of veterinary biologicals.